m 6 A target microRNAs in serum for cancer detection

Recent studies have revealed the significant dysregulation of m A level in peripheral blood in several cancer types and its value in diagnosis. Nonetheless, a biomarker for accurate screening of multiple cancer types has not been established based on the perspective of m A modification. In this stud...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer 2021-12, Vol.20 (1), p.170
Main Authors: Zhang, Bo, Chen, Zhenmei, Tao, Baorui, Yi, Chenhe, Lin, Zhifei, Li, Yitong, Shao, Weiqing, Lin, Jing, Chen, Jinhong
Format: Article
Language:English
Subjects:
Adenosine - analogs & derivatives
Adenosine - metabolism
Biomarkers, Tumor
Circulating MicroRNA
Computational Biology - methods
Diagnosis, Differential
Gene Expression Profiling
Humans
Liquid Biopsy
MicroRNAs - blood
MicroRNAs - genetics
Neoplasms - blood
Neoplasms - diagnosis
Neoplasms - genetics
Prognosis
Reproducibility of Results
ROC Curve
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent studies have revealed the significant dysregulation of m A level in peripheral blood in several cancer types and its value in diagnosis. Nonetheless, a biomarker for accurate screening of multiple cancer types has not been established based on the perspective of m A modification. In this study, we aimed to develop a serum diagnostic signature based on the m A target miRNAs for the mass detection of cancer. A total of 14965 serum samples with 12 cancer types were included. Based on training cohort (n=7299), we developed the m6A-miRNAs signature using a support vector machine algorithm for cancer detection. The m6A-miRNAs signature showed high accuracy, and its area under the curve (AUC) in the training, internal validation and external validation cohort reached 0.979 (95%CI 0.976 - 0.982), 0.976 (95%CI 0.973 - 0.979) and 0.936 (95%CI 0.922 - 0.951), respectively. In the performance of distinguishing cancer types, the m6A-miRNAs signature showed superior sensitivity in each cancer type and presented a satisfactory AUC in identifying lung cancer, gastric cancer and hepatocellular carcinoma. Additionally, the diagnostic performance of m6A-miRNAs was not interfered by the gender, age and benign disease. In short, this study revealed the value of serum circulating m A miRNAs in cancer detection and provided a new direction and strategy for the development of novel biomarkers with high accuracy, low cost and less invasiveness for mass cancer screening, such as RNA modification.
ISSN:1476-4598